HBW-3220

HBW-3220 is a novel, reversible, non-covalent small molecule inhibitor of Bruton's tyrosine kinase (BTK), developed by Chengdu Hyperway Pharmaceuticals. It is designed as a next-generation BTK inhibitor with improved potency and selectivity compared to existing non-covalent BTK inhibitors such as pirtobrutinib and nemtabrutinib. HBW-3220 demonstrates potent inhibition against both wild-type BTK and several clinically relevant BTK mutants (including C481S, C481R, T474I, T316A, L528W) that are associated with resistance to earlier-generation covalent and non-covalent BTKi therapies. Additionally, it inhibits hematopoietic cell kinase (HCK), which contributes to resistance in kinase-defective BTK cases. The drug is being evaluated primarily for relapsed/refractory B-cell malignancies including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Waldenstrom macroglobulinemia (WM) and other mature B-cell lymphomas[1][2][3][4][5][6]. Early clinical data indicate good tolerability at doses up to 150 mg daily with promising efficacy in heavily pretreated patients.